Sandu Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022
For the full year, sales was INR 655.01 million compared to INR 587.55 million a year ago. Revenue was INR 655.83 million compared to INR 589.49 million a year ago. Net income was INR 15.9 million compared to INR 10.93 million a year ago. Basic earnings per share from continuing operations was INR 1.99 compared to INR 1.54 a year ago. Diluted earnings per share from continuing operations was INR 1.87 compared to INR 1.54 a year ago.